Moderna's Phase 3 COVID-19 Vaccine Shows 95% Efficacy

Moderna MRNA announced on Monday the results from phase 3 trials for the COVID-19 vaccine show the vaccine is 94.5% effective. This comes just one week after Pfizer PFE and BioNTech's BNTX vaccine candidate showed a 90% efficacy rate.

The Findings: Moderna based its data on 95 participants with confirmed cases of COVID-19. Findings showed 90 cases of COVID-19 were observed in the placebo group versus 5 cases observed in the mRNA-1273 group, resulting in a point estimate of vaccine efficacy of 94.5%.

In two weeks after the second dose of the vaccine, the researchers report that the vaccine has an efficacy of 94.5%.

Special Storage: The vaccine is expected to remain stable at standard refrigerator temperatures of 2 degrees to 8 degrees Celsius (36 degrees to 46 degrees Fahrenheit) for 30 days, up from the previous estimate of seven days. No dilution required prior to vaccination.

Next Step: Moderna now intends to submit for an Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration in the coming weeks and anticipates having the EUA informed by the final safety and efficacy data (with a median duration of at least two months).

Moderna also plans to submit applications for authorizations to global regulatory agencies.

"This is a pivotal moment in the development of our COVID-19 vaccine candidate," said Stéphane Bancel, CEO of Moderna. "Since early January, we have chased this virus with the intent to protect as many people around the world as possible. All along, we have known that each day matters. This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease."

MRNA Price Action: Moderna shares were trading up 15.6% at $103.04 at the time of publication. The stock has a 52-week high of $95.21 and a 52-week low of $17.68.

Posted In: CoronavirusCovid-19NewsHealth CareTop StoriesGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.